Startups’ Patch Technologies Could Extend Reach of Vaccines
Live MintIn several countries the effort to eradicate measles runs into the logistical obstacle of insufficient cold storage for vaccines. Patches from startups including Micron Biomedical and Vaxxas could overcome this difficulty and extend the reach of vaccines in nations where measles outbreaks occur because of relatively low vaccination rates. The company, which recently increased its Series A venture funding to $17 million, in May said it received promising results from an early study of a vaccine patch for measles and rubella—another viral disease—that was conducted in Gambia, a West African country. The study of its measles-rubella patch in Gambia found that the patch triggered an immune response similar to an injected vaccine, Micron said in May. Patches are a promising approach because they could be a solution to challenges such as the need for cold storage and patients’ preference to avoid needles, said Glenn Rockman founder and managing partner of Adjuvant Capital, a venture-capital firm that invests in startups seeking to make medical care more accessible in developing countries, which hasn’t invested in Micron or Vaxxas.
History of this topic
Oxfordshire-based company creates Covid vaccines given in a skin patch
Daily Mail
Covid vaccine could soon be needle-free after invention from Australian scientists
Daily MailDiscover Related
)
)
